capecitabine / Generic mfg. - LARVOL DELTA

Efficacy and safety of PRRT for the treatment of pancreatic neuroendocrine tumors: Systematic review and meta-analysis. (PubMed, Bull Cancer) - "PRRT is a promising therapeutic option for patients with advanced pNETs, offering a balance of efficacy and safety compared to other available treatments. Full dosage PRRT may provide better outcomes than reduced dosages, and salvage PRRT remains effective for progressive disease. However, further high-quality RCTs are needed to confirm these findings and optimize PRRT usage in pNETs."

Journal • Retrospective data • Review • Gastrointestinal Neuroendocrine Tumor • Hematological Disorders • Neuroendocrine Tumor • Oncology • Pancreatic Cancer • Solid Tumor

Disseminated Superficial Actinic Porokeratosis in a Woman With Metastatic Pancreatic Cancer During Chemotherapy With Capecitabine and Nab-Paclitaxel. (PubMed, Australas J Dermatol) - "We report a case of disseminated superficial actinic porokeratosis (DSAP) in a 73-year-old woman with metastatic pancreatic cancer undergoing chemotherapy with capecitabine and nab-paclitaxel. This case suggests a possible association between DSAP and the use of these chemotherapeutic agents, emphasising the need for awareness of atypical dermatologic reactions in such patients."

Journal • Oncology • Pancreatic Cancer • Solid Tumor

Identifying actionable genetic mutations and microsatellite instability in liquid biopsy of colorectal cancer. (PubMed, J Genet Eng Biotechnol) - "CRC genetic mutational statuses as well as contributing environmental stress factors such as gut microbiota dysbiosis are prognostically crucial, associated with high risk potential of gene-environment interactions based on machine learning."

Journal • Liquid biopsy • Colorectal Cancer • Infectious Disease • Microsatellite Instability • Oncology • Solid Tumor • FGFR3 • KDR • MSI • PIK3CA • TP53

A predictive model for life-threatening fluoropyrimidine toxicity based on DPYD sequencing in colorectal cancer. (PubMed, J Natl Cancer Inst) - "DPYD sequencing identified additional relevant variants and improved the sensitivity of DPYD testing. An online calculator (https://fluoropyrimidine-toxicity-predictor.gustaveroussy.fr/) is provided to estimate the individual probability of developing life-threatening toxicity, based on clinical covariates and extended DPYD genotype."

Journal • Colorectal Cancer • Hematological Disorders • Oncology • Solid Tumor • DPYD

Dual Cardiotoxicity of Capecitabine: Coronary Vasospasm and QT Prolongation in a Patient with Gastric Adenocarcinoma. (PubMed, JACC Case Rep) - "This case illustrates the dual cardiotoxicity of capecitabine, with both vasospastic angina and QT prolongation."

Journal • Cardiovascular • Gastric Adenocarcinoma • Gastric Cancer • Gastrointestinal Cancer • Oncology • Pain • Pulmonary Disease • Solid Tumor

Atypical hemolytic uremic Syndrome Triggered by malignancy and drug exposure: A systematic review and meta-analysis (ASH 2025) - "Tacrolimus was the mostreported drug trigger (n=6)followed by gemcitabine (n=5), vincristine (n=5), bevacizumab (n=3), carfilzomib (n=3), 6-mercaptopurine(n=2), methotrexate (n=2), and mitomycin (n=2). Aflibercept, bactrim, bleomycin, capecitabine, cisplatin, cyclophosphamide, cytarabine,dasatinib, deferasirox, dinutuximab, estarylla, ketoprofen, L-asparaginase, modakafusp alfa, PEG-asparaginase, sunitinib, syntheticpsychoactive drugs, tamoxifen, and topotecan were reported as potential triggers for aHUS in one patient each...The pooled rate of treatment with eculizumab was 74% (95% CI, 0.629-0.842, p < 0.01, I2 = 72%),and the pooled rate of renal recovery was 65% (95% CI, 0.525-0.761, p < 0.01, I2 = 55%)...AKI and hematological abnormalities in these patients should prompt an emergent work-up and treatment. Current evidenceis primarily derived from case reports, so prospective trials are necessary to establish the incidence, associations, triggers, and outcomes..."

Retrospective data • Review • Acute Kidney Injury • Acute Lymphocytic Leukemia • Anemia • Atypical Hemolytic Uremic Syndrome • B Acute Lymphoblastic Leukemia • Biliary Cancer • Breast Cancer • Cholangiocarcinoma • Complement-mediated Rare Disorders • Genito-urinary Cancer • Hematological Malignancies • Hepatocellular Cancer • Hodgkin Lymphoma • Leukemia • Lung Cancer • Lymphoma • Multiple Myeloma • Nephrology • Neuroblastoma • Oncology • Ovarian Cancer • Pancreatic Cancer • Prostate Cancer • Renal Cell Carcinoma • Renal Disease • Solid Tumor • Thrombocytopenia • Urothelial Cancer

Overall survival (OS) in patients with metastatic colorectal cancer (mCRC) following persistent chemotherapy-induced thrombocytopenia (pCIT) (ASH 2025) - "pCIT was defined as the first occurrence of a platelet countmeasurement ≤85×109/L, ≥13 days after the nearest prior chemotherapy administration with fluorouraciland oxaliplatin (FOLFOX) or fluorouracil, irinotecan, and oxaliplatin (FOLFOXIRI); or ≥ 20 days afteroxaliplatin and capecitabine (CAPOX)... The median OS for mCRC patients following the first pCIT ranges from 9.7 to 23.5 months,with 6-month survival probabilities between 64% and 90%, across different LOTs. Multiple factors, suchas LOT, ECOG, age, CIT grade, and bevacizumab use, are associated with clinically relevant differences insurvival in patients with pCIT. These findings provide clinically relevant benchmarks for survival and maybe useful in assessing the need for supportive therapy."

Clinical • Metastases • Colorectal Cancer • Oncology • Solid Tumor • Thrombocytopenia

Hypo-fractionated radical radiotherapy with concurrent mitomycin C and capecitabine in muscle-invasive bladder cancer – A single institution prospective phase II study (ESMO Asia 2025) - "Background: Chemoradiotherapy with Mitomycin C (MMC) and 5-fluorouracil is the standard non-surgical treatment for non-metastatic muscle invasive bladder cancer. Hypofractionated radical radiotherapy with MMC and capecitabine in patients with muscle-invasive bladder cancer unfit or unwilling for surgery is well tolerated, with acceptable toxicity and high compliance. We recommend testing this schedule in future phase III studies in bladder cancer."

Clinical • P2 data • Bladder Cancer • Gastrointestinal Cancer • Genito-urinary Cancer • Oncology • Solid Tumor

Long-Term Disease Control with Combined Immunotherapy and Oral Chemotherapy in Primary Intraosseous Adenoid Cystic Carcinoma of the Mandible with Initial Pulmonary Metastasis (ESMO Asia 2025) - "Two cycles of docetaxel + sintilimab followed, but severe nausea/vomiting led to discontinuation of intravenous chemotherapy. Oral fluoropyrimidines (S-1, capecitabine) are favorable for maintenance due to low toxicity. ACC, an immunologically "cold" tumor, typically responds poorly to immunotherapy, but combined sintilimab and oral capecitabine here enabled prolonged control, suggesting potential for advanced PIACC."

Adenoid Cystic Carcinoma • Oncology

Triple-negative breast cancer with somatic BRCA1 mutation and metaplastic progression in a young woman: A case report (ESMO Asia 2025) - "She underwent modified radical mastectomy with sentinel lymph node biopsy, followed by adjuvant doxorubicin–cyclophosphamide (AC) for 4 cycles, which was complicated by pneumonitis and heart failure. Weekly paclitaxel for 11 cycles was discontinued due to fatigue and elevated troponin, despite a normal ECG...She received gemcitabine–cisplatin for 2 cycles with stable disease, followed by cytoreductive palliative surgery with reconstruction, and then 2 additional cycles of gemcitabine–cisplatin...She was treated with docetaxel–capecitabine for 1 cycle with poor response, followed by sacituzumab govitecan for 3 cycles, which resulted in disease progression. Currently, the patient is on eribulin plus durvalumab, having completed 1 cycle...This case illustrates an unusual histological evolution from medullary carcinoma to metaplastic carcinoma, and subsequently to mucoepidermoid carcinoma. It raises important questions about the optimal timing of genomic testing and the..."

Case report • Clinical • IO biomarker • Tumor mutational burden • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Negative Breast Cancer • Oncology • Salivary Gland Cancer • Solid Tumor • Squamous Cell Carcinoma • Triple Negative Breast Cancer • BRCA • BRCA1 • HER-2 • PD-L1 • PGR • PTEN • RB1 • SF3B1 • STK11 • TMB • TP53

Frequency of dihydropyrimidine dehydrogenase (DPD) deficiency in patients receiving fluoropyrimidine-based chemotherapy for solid tumors: A single-centre experience in Dubai, UAE (ESMO Asia 2025) - "Background: Dihydropyrimidine dehydrogenase (DPD) deficiency, caused by variants in the DPYD gene, is found in 3-5% of the population and significantly increases the risk of severe toxicity in patients receiving fluoropyrimidine chemotherapy such as 5-fluorouracil (5-FU)...The most frequently used regimens were CAPOX (n = 34, 33%), FOLFOX (n = 32, 31%), single-agent capecitabine (n = 18, 17%), FOLFIRINOX (n = 8, 8%), and FLOT (n = 5, 4%)... In our cohort, the prevalence of clinically significant DPYD mutations was lower than reported in global literature. These findings highlight the need for larger, region-specific studies to better understand DPYD variant frequencies in the Gulf region and to optimize individualized chemotherapy dosing."

Clinical • Colorectal Cancer • Oncology • Solid Tumor • DPYD

Prophylactic effect of diclofenac sodium gel on hand-foot syndrome in patients with gastrointestinal cancer treated with tyrosine kinase inhibitors : A single-center prospective observational study (ESMO Asia 2025) - "Secondary endpoints included overall survival (OS), progression-free survival (PFS), safety, tolerability, and QOL (The HFS-14 questionnaire). Between January 2024 and May 2025, 31 patients were enrolled (median age: 67 years [range: 51-80]; male/female: 58%/42%; performance status [PS] 0/1/2: 36%/61%/3%; primary tumor site: colorectal/hepatocellular carcinoma/gastrointestinal stromal tumor: 77%/16%/7%; TKIs: regorafenib/lenvatinib/fruquintinib/sorafenib/sunitinib: 77%/10%/7%/3%/3%. Diclofenac sodium gel application did not reduce the incidence of TKIs-induced grade ≥2 HFS, compared to than the known reports of capecitabine-induced HFS. However, there were no grade≥ 3 HFS and treatment discontinuation due to HFS. Further research on the preventive effects of diclofenac sodium gel for HFS induced by TKIs is warranted."

Clinical • Observational data • Colorectal Cancer • Gastric Cancer • Gastrointestinal Cancer • Gastrointestinal Stromal Tumor • Hepatocellular Cancer • Oncology • Sarcoma • Solid Tumor

Capecitabine dosage as a prognostic factor for the development of hand-foot syndrome: A competing risk analysis (ESMO Asia 2025) - "Background: Capecitabine is an oral prodrug of 5-fluorouracil (5-FU) widely used in the treatment of various solid tumors. This study confirms capecitabine dosage as an independent prognostic factor for grade 2–3 HFS, with significantly increased risk at a dosage of 4000 mg/day. The use of competing risk analysis strengthens causal inference and provides more accurate risk estimates. These findings underscore the importance of careful dosing and support the implementation of evidence-based strategies for dose adjustment in high-risk patients."

Biomarker • Oncology • Solid Tumor

Adebrelimab combined with Celecoxib and chemotherapy as first-line treatment for PD-L1-positive and HER2-negative locally advanced gastric/gastroesophageal junction adenocarcinoma: A single-arm, exploratory clinical trial (ESMO Asia 2025) - P4 | "Eligible patients will receive a combination of adebrelimab, celecoxib, and either XELOX or SOX, administered once every 21-day cycle, and continued until disease progression, unacceptable toxicity, withdrawal of informed consent, or investigator-determined study termination. The secondary endpoints include disease control rate, duration of response, progression-free survival, overall survival, and safety. Exploratory endpoints included the correlation between COX-2 expression and treatment efficacy and prognosis, as well as the association of cytokines IL-6, IL-8, and IL-10 with efficacy and prognosis."

Clinical • IO biomarker • Metastases • Esophageal Cancer • Gastric Adenocarcinoma • Gastroesophageal Junction Adenocarcinoma • Oncology • Solid Tumor • CXCL8 • HER-2 • IL10 • IL6 • PTGS2

Comparative survival and toxicity outcomes of perioperative versus adjuvant chemotherapy in resectable gastric cancer: A real-world cohort study (ESMO Asia 2025) - "Of these, 51 (48%) received NACT with platinum–fluoropyrimidine ± taxane, and 55 (52%) received ADJ with S-1 or capecitabine/oxaliplatin following upfront gastrectomy... Perioperative and adjuvant chemotherapy yielded comparable survival after D2 gastrectomy, though NACT caused higher toxicity. The numerical RFS advantage with adjuvant therapy warrants prospective evaluation. Treatment choice should be individualised."

Clinical • Real-world • Real-world evidence • Esophageal Cancer • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Oncology • Solid Tumor

Comparison of efficacy and safety of capecitabine plus mitomycin, 5-FU plus mitomycin, and 5-FU plus cisplatin regimens for definitive chemoradiotherapy in anal squamous cell carcinoma: A single-center retrospective study (ESMO Asia 2025) - "Although CRT regimens, such as capecitabine plus mitomycin (Cape+MMC), 5-fluorouracil plus mitomycin (FU+MMC), and 5-fluorouracil plus cisplatin (FP) are widely used, their comparative efficacy and safety remain unclear. Cape+MMC, FU+MMC, and FP regimens showed comparable efficacy with acceptable safety profiles in patients with stage I–III ASCC. Given the high CR and survival rates, all three regimens may be considered viable treatment options."

Retrospective data • Anal Carcinoma • Oncology • Squamous Cell Carcinoma

Integrative Immune profiling reveals early predictors of response and prognosis in advanced gastric cancer treated with Nivolumab plus chemotherapy (ESMO Asia 2025) - "This study evaluated plasma immune markers and peripheral immune cell subsets in patients treated with nivolumab plus chemotherapy, focusing on their associations with treatment response and survival outcomes. Fifty patients with metastatic or unresectable advanced gastric cancer treated with nivolumab (360 mg every 3 weeks or 240 mg every 2 weeks) plus chemotherapy (capecitabine/oxaliplatin or leucovorin/fluorouracil/oxaliplatin) at Seoul St. Early increases in cytotoxic and chemokine markers, as well as specific baseline immune-checkpoint and memory T-cell profiles, may help predict treatment response and prognosis in advanced gastric cancer patients receiving nivolumab plus chemotherapy. These findings support the integration of immune monitoring into clinical decision-making."

IO biomarker • Metastases • Gastric Cancer • Oncology • Solid Tumor • CD8 • CXCL10 • GZMB • HAVCR2 • IFNG • LAG3 • PD-1 • TGFB1

Paradox of perioperative chemotherapies FLOT (fluorouracil plus leucovorin, oxaliplatin and docetaxel) vs EOX (Epirubicin, oxaliplatin and capecitabine) in non-metastatic gastric carcinoma survival– A retrospective analysis (ESMO Asia 2025) - "FLOT regimen showed nonsignificant favourable survival outcomes and tumour downstaging. The OS/PFS outcomes are less compared to randomised studies. Need prospective study comparing EOX vs FLOT as well as molecular exploratory research."

Metastases • Retrospective data • Gastric Cancer • Oncology • Solid Tumor

Zolbetuximab plus mFOLFOX6/CAPOX as first-line (1L) treatment in patients with claudin 18 isoform 2 positive (CLDN18.2+) metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma with peritoneal metastases: A post hoc analysis of SPOTLIGHT and GLOW (ESMO Asia 2025) - P3 | "The phase 3 SPOTLIGHT (NCT03504397) and GLOW (NCT03653507) trials showed survival benefits of 1L zolbetuximab plus modified fluorouracil, leucovorin, and oxaliplatin regimen (mFOLFOX6)/capecitabine and oxaliplatin (CAPOX) vs placebo (PBO) plus mFOLFOX6/CAPOX in patients with CLDN18.2+, human epidermal growth factor receptor 2 (HER2)−, locally advanced (LA) unresectable or mG/GEJ adenocarcinoma. This post hoc analysis showed numeric PFS and OS improvements with 1L zolbetuximab plus chemotherapy vs PBO plus chemotherapy in patients with CLDN18.2+, HER2−, LA unresectable or mG/GEJ adenocarcinoma with baseline peritoneal metastases. Safety events were similar compared to patients in the pooled intent-to-treat population."

Clinical • Metastases • Retrospective data • Gastroesophageal Junction Adenocarcinoma • Oncology • CLDN18 • HER-2

First-line (1L) trastuzumab deruxtecan (T-DXd) 5.4 mg/kg + fluoropyrimidine (FP) + pembrolizumab (pembro) in advanced HER2+ gastric cancer (GC), gastroesophageal junction adenocarcinoma (GEJA), or esophageal adenocarcinoma: updated results from DESTINY-Gastric03 (DG-03) Part 2F (ESMO Asia 2025) - P2 | "In arm 2F, pts received T-DXd 5.4 mg/kg IV Q3W + reduced-dose FP (5-fluorouracil 600 mg/m2/day, CIV, Days 1–5 Q3W or capecitabine 750 mg/m2, BID, Days 1–14 Q3W) + pembro 200 mg IV Q3W. Results provide further evidence of antitumor activity with 1L T-DXd 5.4 mg/kg + reduced-dose FP + pembro in HER2+ GCs, with no new safety signals observed; ORRs were consistent irrespective of PD-L1 status. Data support the ongoing studies with this 1L T-DXd triplet regimen in HER2+ GCs."

Clinical • Metastases • Esophageal Adenocarcinoma • Esophageal Cancer • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Oncology • Solid Tumor • HER-2 • PD-L1

Adjuvant envafolimab combined with capecitabine and lenvatinib versus conventional therapy in resected biliary tract cancer with high-risk recurrence factors: A propensity score-matched analysis (ESMO Asia 2025) - P2/3 | "The adjuvant ECL regimen significantly improved DFS and 1-year OS rate compared to CT in resected BTC patients with high-risk recurrence factors. These promising results warrant further validation in randomized controlled trials to establish its potential as a new standard adjuvant therapy."

Clinical • Biliary Cancer • Biliary Tract Cancer • Oncology • Solid Tumor

Real-world observational study of fruquintinib in combination with irinotecan and capecitabine as second-line treatment in patients with advanced colorectal cancer (ESMO Asia 2025) - P | "11 (52.4%) and 4 (19.0%) patients had received bevacizumab and cetuximab as part of their first-line treatment. These results show the preliminary efficacy and safety of fruquintinib in combination with irinotecan and capecitabine as a second-line treatment for patients with advanced colorectal cancer."

Clinical • Combination therapy • Metastases • Observational data • Real-world • Real-world evidence • Colorectal Adenocarcinoma • Colorectal Cancer • Oncology • Solid Tumor • UGT1A1

First-line systemic therapy outcomes in patients with isolated peritoneal metastases from colorectal cancer: Real-world data from Vietnam (ESMO Asia 2025) - "Treatment regimens included oxaliplatin-based (XELOX/FOLFOX) or irinotecan-based (XELIRI/FOLFIRI) combinations, with bevacizumab added in 82.2% of cases... In Vietnamese real-world cohort, first-line chemotherapy demonstrated clinically meaningful outcomes in patients with IPM from CRC. These preliminary findings highlight the feasibility of systemic chemotherapy for this challenging subgroup. Further analysis of prognostic factors and regimen specific efficacy is ongoing."

Clinical • Real-world • Real-world evidence • Colorectal Cancer • Oncology • Solid Tumor

Mitoxantrone hydrochloride liposome (Lipo-MIT) combined with capecitabine in HER2-negative advanced breast cancer: A dose-escalation, phase I study (ESMO Asia 2025) - P=N/A | "The combination of Lipo-MIT and Capecitabine demonstrated manageable safety and antitumor activity in pretreated HER2-negative ABC pts. The MTD of Lipo-MIT was not reached, and the RP2D of Lipo-MIT is 22 mg/m2 every 4 weeks with capecitabine."

Metastases • P1 data • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Negative Breast Cancer • Oncology • Solid Tumor • HER-2

Early experience in using tissue-free minimal residual disease (MRD) testing in breast cancer patients from Asia and the Middle East (ESMO Asia 2025) - "A patient with stage III TNBC after capecitabine 6 cycles was reported MRD (+), but based on the normal biomarkers and scan, there was no change in therapy... MRD testing in BC is predominantly being used in the surveillance phase; tissue-free MRD test could be implemented with fast TAT to support escalation and de-escalation strategies in treatment."

Clinical • Minimal residual disease • Residual disease • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • HER-2